Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

JW To Progress Dendritic Cell Therapeutics After Fund Raising

This article was originally published in PharmAsia News

Executive Summary

South Korea's JW Group is accelerating efforts to develop cancer immune cell therapies by raising a total of KRW50bn ($42.9m), with the funds to be used for its novel drug development arm JW CreaGene, which has a number of innovative dendritic cell-based candidates in the pipeline.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC089407

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel